Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-58.55% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
-78.48% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-32.26% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-4.78% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
14.56% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
14.56% |
| Date | Value |
|---|
| Mar 31, 2026 |
14.56% |
| Dec 31, 2025 |
-47.39% |
| Sep 30, 2025 |
6.48% |
| Jun 30, 2025 |
-17.85% |
| Mar 31, 2025 |
-93.57% |
| Dec 31, 2024 |
-35.52% |
| Sep 30, 2024 |
39.23% |
| Jun 30, 2024 |
-110.50% |
| Mar 31, 2024 |
-415.75% |
| Dec 31, 2023 |
51.52% |
| Sep 30, 2023 |
-24.39% |
| Jun 30, 2023 |
-37.36% |
| Mar 31, 2023 |
-32.84% |
| Dec 31, 2022 |
28.05% |
| Sep 30, 2022 |
-84.09% |
| Jun 30, 2022 |
-33.96% |
| Mar 31, 2022 |
-55.25% |
| Dec 31, 2021 |
31.51% |
| Sep 30, 2021 |
-87.95% |
| Jun 30, 2021 |
36.03% |
